跳至主要内容
临床试验/DRKS00017383
DRKS00017383已完成未知

sing the joystick against pathological gambling: An experimental clinical study in inpatient rehabilitation patients to assess the therapeutic efficacy of a neurocognitive training - Joystick

Institut für Therapie- und Gesundheitsforschung (IFT-Nord) gGmbH0 个研究点目标入组 214 人开始时间: 2019年6月3日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
214

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 55 Years(—)
性别
All

入选标准

  • positive screening for pathological gambling (via Kurzfragebogen zum Glücksspielverhalten)
  • - sufficient German language capacity

排除标准

  • - organic or psychotic disorder
  • - bipolar disorder
  • - major depression
  • - suicidal tendency
  • Depression measured with the BDI (Beck Depression Inventory).

研究者

发起方
Institut für Therapie- und Gesundheitsforschung (IFT-Nord) gGmbH

相似试验

尚未招募
不适用
The use of educational game as a strategy to confront the childhood obesityObesity
RBR-7sm6qjEscola de Educação Física e Esporte de Ribeirão Preto
招募中
不适用
BEAT IT! Training behavioral control in adolescents.increasing behavioral control and reducing (heavy) alcohol usekeywords EN: serious gaming, behavioral control, alcohol use, adolescents, delay of gratificationkeyword NL: serious gaming, gedragscontrole, alcohol gebruik, adolescenten, uitstel van beloning
NL-OMON28915trecht University, Dynamics of Youth150
招募中
不适用
Karman Line: Strategy-game supported treatment for slowed information processing speed (IPS)
NL-OMON51933Revalidatiecentrum Groot Klimmendaal60
进行中(未招募)
不适用
Study to test whether PF-00547659 is safe and improves disease symptoms in patients with Crohn's disease that have not responded to other treatmentsMedDRA version: 16.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's Disease
EUCTR2010-023437-30-SKPfizer Inc., 235 East 42nd Street, New York, NY 10017240
进行中(未招募)
不适用
A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of PF-04236921 in Subjects with Crohn's Disease Who are Anti-TNF Inadequate ResponsersCrohn's Disease (active moderate to severe)MedDRA version: 16.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2010-023034-23-SEPfizer Inc., 235 East 42nd Street, New York, NY 10017220